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congestive heart failure, coronary artery disease, lung
disease, and renal insufficiency.2-5 In light of the
increasing age and comorbidity of patients who need
valve replacement, further knowledge is necessary to
determine the most effective treatment. Few large stud-
ies exist that compare biologic with mechanical pros-
theses, and even fewer studies describe the influence of
comorbid illness on outcome over a 10-year period,
which is often the remaining life-span of these
patients.6-11 Although any adverse outcome can be cost-
ly, the influence of prosthesis type on health care cost
remains even less well defined.12 
The purpose of this study was to examine the deter-
minants of outcome after biologic versus mechanical
aortic valve replacement as might be relevant in the
selection of a biologic versus a mechanical prosthesis.
M ore than 20 years after the introduction of modernprostheses, the choice of biologic versus mechani-
cal aortic valve prostheses remains difficult.1 The clini-
cal decision becomes even more challenging in the
presence of coexisting conditions such as advanced age,
Objective: The purpose of this study was to optimize selection criteria of
biologic versus mechanical valve prostheses for aortic valve replace-
ment. Methods: Retrospective analysis was performed for 841 patients
undergoing isolated, first-time aortic valve replacement with
Carpentier-Edwards (n = 429) or St Jude Medical (n = 412) prostheses.
Results: Patients with Carpentier-Edwards and St Jude Medical valves
had similar characteristics. Ten-year survival was similar in each group
(Carpentier-Edwards 54% ± 3% versus St Jude Medical 50% ± 6%; P
= .4). Independent predictors of worse survival were older age, renal or
lung disease, ejection fraction less than 40%, diabetes, and coronary dis-
ease. Carpentier-Edwards versus St Jude Medical prostheses did not
affect survival (P = .4). Independent predictors of aortic valve reopera-
tion were younger age and Carpentier-Edwards prosthesis. The lin-
earized rates of thromboembolism were similar, but the linearized rate
of hemorrhage was lower with Carpentier-Edwards prostheses (P < .01).
Perivalvular leak within 6 months of operation was more likely with St
Jude Medical than with Carpentier-Edwards prostheses (P = .02).
Estimated 10-year survival free from valve-related morbidity was better
for the St Jude Medical valve in patients aged less than 65 years and was
better for the Carpentier-Edwards valve in patients aged more than 65
years. Patients with renal disease, lung disease (in patients more than
age 60 years), ejection fraction less than 40%, or coronary disease had a
life expectancy of less than 10 years. Conclusions: For first-time, isolated
aortic valve replacement, mechanical prostheses should be considered in
patients under age 65 years with a life expectancy of at least 10 years.
Bioprostheses should be considered in patients over age 65 years or with
lung disease (in patients over age 60 years), renal disease, coronary dis-
ease, ejection fraction less than 40%, or a life expectancy less than 10
years. (J Thorac Cardiovasc Surg 1999;117:890-7)
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Although many surgeons have agreed that younger and
healthier patients should receive mechanical valves and
older and sicker patients should receive bioprosthetic
valves, a large difference in opinion exists as to the
appropriate management of valvular disease in patients
between ages 60 and 70 years who often have multiple
comorbidities.13 This retrospective analysis from one
institution investigates whether the outcomes of
patients who underwent aortic valve surgery differ with
the use of mechanical versus bioprosthetic valves. An
algorithm for prosthesis selection in patients with aor-
tic valvular disease is proposed.
Methods
From 1976 to 1996, 1676 patients underwent aortic valve
replacement at Duke University Medical Center. To obtain a
more homogeneous population, we excluded patients under-
going a concurrent operation for placement of another valve,
patients aged less than 18 years, patients receiving valves
sized less than 19 mm, and patients with a previous sternoto-
my. To further improve population homogeneity and to elim-
inate prostheses that are now less used, we also excluded 489
patients who by surgeon preference received aortic homo-
grafts or prostheses used in small numbers. The resultant
study population consisted of all 841 patients undergoing iso-
lated, first-time aortic valve replacement with the Carpentier-
Edwards (CE) standard porcine prosthesis (n = 429; model
2625; Baxter Healthcare Corp, Irvine, Calif) or the St Jude
Medical (SJ) prosthesis (n = 412; model A102; St Jude
Medical, Inc, St Paul, Minn). As of 1996, follow-up was
100% complete, that is, all patients were known to be either
dead or alive on January 1, 1996. Data were obtained from
chart review (18%), telephone interview (43%), the National
Death Index (33%), or autopsy (6%).
All aortic valve operations were performed through a medi-
an sternotomy with the use of cardiopulmonary bypass and
crystalloid or blood cardioplegic solution. Patients with bio-
prostheses were generally started on long-term aspirin thera-
py beginning on the first postoperative day.14 Patients with
mechanical prostheses were started on warfarin sodium
(Coumadin) therapy on postoperative day 2, either with or
without aspirin therapy. Most patients with a mechanical
valve were followed up by their local physicians to maintain
an international normalized ratio of 2.0 to 3.0.
Outcomes were defined according to the standard defini-
tions.15 Renal disease was identified as a preoperative creati-
nine level greater than 2.0 mg/dL. Pulmonary disease includ-
ed any ongoing pulmonary diagnosis requiring treatment.
Coronary diameter reduction of 75% or more was considered
to be significant. Endocarditis was defined as a clinical diag-
nosis of endocarditis. Valve-related morbidity was considered
to be any hemorrhage, thromboembolism, aortic valve reop-
eration, or endocarditis. Perivalvular leak was defined as
moderate or severe aortic regurgitation not the result of pros-
thetic dysfunction.
Data were analyzed with SAS software release 6.12 (SAS
Institute, Cary, NC). Continuous data were expressed as
mean ± SD. Comparisons of the 2 groups were made with the
Mann-Whitney U test for continuous data not distributed nor-
mally. Cox proportional hazards regression model was used
in the survival and valve-related outcome analysis. The
assumptions of the proportional hazards model were checked
graphically. The variables of age and ejection fraction were
stratified or converted to binary form to accommodate a non-
linear relationship to risk. Variables were selected for models
by a forward and backward stepwise elimination procedure.
All univariable factors significant at P < .10 were examined.
All the statistical analyses were conducted with a = .05. To
obtain estimates of 10-year survival free of valve-related
morbidity in selected age groups where several groups con-
tained fewer than 10 patients, log curve fitting was used16
Fig 1. Estimated survival free from valve-related morbidity
10 years after aortic valve replacement with the CE or SJ
prostheses as a function of patient age (year).
Table I. Preoperative patient characteristics
CE SJ 
(n = 429) (n = 412) P value
Age (y) 64 ± 12 62 ± 13 NS
Year of operation 1984 ± 5 1990 ± 3 .001
Male (%) 307 (72) 243 (59) .001
Ejection fraction 50 ± 15 51 ± 14 NS
Atrial fibrillation (%) 67 (16) 55 (13) NS
Coronary disease (%) 178 (41) 169 (41) NS
Valve size (mm) 24 ± 3 23 ± 3 .001
Diabetes (%) 45 (10) 82 (20) .001
Heart failure class 2.9 ± 1.0 3.0 ± 1.0 NS
Angina class 2.1 ± 1.2 2.0 ± 1.2 NS
Endocarditis (%) 22 (5) 8 (2) .001
Lung disease (%) 82 (19) 62 (15) NS
Cerebrovascular disease (%) 41 (10) 42 (10) NS
Renal disease (%) 28 (7) 13 (3) .02
Peptic ulcer disease (%) 47 (11) 44 (11) NS
Gastrointestinal bleed (%) 21 (5) 16 (4) NS
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(Fig 1). Actual (versus actuarial) freedom from events was
computed by the method of Grunkemeier and associates.17
Kaplan-Meier curves were compared by the log rank test.
Results
Patients with a CE prosthesis and an SJ prosthesis did
not differ significantly in age (Table I). Coronary artery
bypass grafting was performed in 152 of 429 patients
(35%) with a CE prosthesis and in 175 of 412 patients
(42%) with an SJ prosthesis (P = NS). In the SJ pros-
thesis group, the number of patients undergoing coro-
nary bypass grafting exceeded the number of patients
with coronary disease because 6 patients received
grafts for vessels with less than 75% diameter reduc-
tion. Patients with a CE prosthesis were more likely to
be male and to have an earlier year of operation and
larger valve size; they were less likely to have diabetes
or renal disease, but more likely to have endocarditis.
However, there was no significant difference in ejec-
tion fraction, coronary disease, angina, or heart failure.
Thirty-day survival. The absolute 30-day mortality
rate was 35 of 429 patients (8% ± 1%) for patients with
a CE prosthesis and 15 of 412 patients (4% ± 1%) for
patients with an SJ prosthesis (P < .01). By logistic
regression, independent predictors of 30-day mortality
were earlier year of operation (c 2 = 8.2; P = .004) and
concurrent coronary bypass grafting (c 2 = 6.3; P = .01).
Valve make (CE versus SJ prosthesis ) was not an inde-
pendent predictor of 30-day mortality (c 2 = 2.6; P =
.10). Thus the higher 30-day mortality rate for patients
with a CE versus an SJ prosthesis was largely attributable
to the earlier year of operation for patients with a CE ver-
sus an SJ prosthesis and the improvement in operative
mortality rate from 1976 to 1996.
Late survival. After aortic valve replacement, there
was no significant difference in survival of patients
receiving a CE versus an SJ prosthesis (54% ± 3% vs
50% ± 6% at 10 years; P = .4; Fig 2). By Cox model
analysis, independent multivariable factors predicting
worse survival included older age, renal disease, ejec-
tion fraction less than 40%, lung disease, coronary
artery disease, and diabetes (Table II). A CE versus an
SJ make of valve (P = .4) and year of operation (P = .5)
were not significant predictors of late survival by mul-
tivariable analysis. Causes of all deaths (early and late)
were not significantly different (P = .8) between
patients with a CE prosthesis and patients with an SJ
prosthesis (Table III).
Valve-related complications. At discharge, 4 of 377
patients (1%) with a CE prosthesis and 364 of 379
patients (96%) with an SJ prosthesis were receiving
warfarin therapy. At last follow-up for living patients,
12 of 171 patients (7%) with a CE prosthesis and 219 of
225 patients (97%) with an SJ prosthesis were receiving
warfarin therapy. Discharge medications were unknown
Fig 2. Patient survival after aortic valve replacement with the
CE or SJ prosthesis.
Table II. Predictors of patient survival
Hazard 
b c
2 P value ratio 95% CI
Age ‡ 65 y .43 ± .13 10.2 .001 2.0 (1.2, 2.0)
EF < 40% .49 ± .14 12.7 .0004 2.1 (1.2, 2.1)
Coronary disease .20 ± .06 12.0 .0005 1.4 (1.1, 1.4)
Lung disease .43 ± .15 8.2 .004 1.5 (1.1, 2.1)
Diabetes .38 ± .16 5.4 .02 1.5 (1.1, 2.0)
Renal disease .80 ± .23 12.3 .0004 2.2 (1.4, 3.5)
CI, Confidence interval.
Table III. Causes of all deaths
CE (n) SJ (n)
Noncardiac (%) 45 (22) 17 (16)
Congestive heart failure (%) 42 (22) 19 (18)
Other cardiac (%) 29 (14) 12 (11)
Infection (%) 14 (7) 7 (7)
Myocardial infarction (%) 12 (6) 9 (9)
Stroke (%) 4 (2) 4 (4)
Sudden (%) 5 (2) 1 (1)
Hemorrhage (%) 1 (0) 2 (2)
Structural valvular deterioration (%) 1 (0) 0 (0)
Unknown (%) 54 (26) 34 (32)
Total 207 105
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in 13 of 390 patients (3%) with a CE prosthesis and in
15 of 394 patients (4%) with an SJ prosthesis; medica-
tions at last follow-up were unknown in 51 of 222
patients (23%) with a CE prosthesis and in 82 of 307
patients (27%) with an SJ prosthesis. Ten-year freedom
from hemorrhage was higher for patients with a CE
prosthesis than for patients with an SJ prosthesis (97%
± 1% vs 91% ± 3%; P = .01; Fig 3). By Cox model
analysis, the only variable predictive of hemorrhage was
SJ valve make (P = .003); patient age did not signifi-
cantly affect hemorrhage. The linearized rate of hemor-
rhage was significantly lower for patients with a CE
prosthesis than for patients with an SJ prosthesis (0.3%
± 0.1%/pt-y versus 1.2% ± 0.3%/pt-y; P = .001). Ten-
year freedom from thromboembolism was not signifi-
cantly different for patients with a CE prosthesis versus
patients with an SJ prosthesis (93% ± 2% vs 94% ± 2%;
P = .9; Fig 3). By Cox model analysis, no variables
including age were identified to be predictive of throm-
boembolism. The linearized rates of thromboembolism
were not significantly different for patients with a CE
prosthesis versus patients with an SJ prosthesis (0.7% ±
0.2%/pt-y vs 1.0% ± 0.3%/pt-y; P = .3). 
Perivalvular leak was noted in 21 of 429 patients (5%)
with a CE prosthesis and 18 of 412 patients (4%) with
an SJ prosthesis (P = .7). Perivalvular leak was treated
Fig 3. Freedom from hemorrhage, thromboembolism, and endocarditis after aortic valve replacement with the CE
or SJ prosthesis.
Fig 4. Freedom from aortic valve reoperation after aortic valve replacement with the CE or SJ prostheses in
patients aged 65 years or less (left panel) or 65 years or more (right panel).
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with reoperation in 12 of 21 patients (57%) with a CE
prosthesis versus 6 of 18 patients (33%) with an SJ
prosthesis (P > .1). Ten-year freedom from perivalvular
leak was not significantly different for patients with a
CE prosthesis versus patients with an SJ prosthesis
(92% ± 2% vs 91% ± 3%; P = .3). Perivalvular leak was
significantly more likely to be noted in the first 6
months after operation with an SJ versus a CE prosthe-
ses (8 of 412 patients [1.9%] vs 1 of 429 patients
[0.2%]; P = .02). The linearized rate of perivalvular leak
was 0.7% ± 0.1%/pt-y for a CE prosthesis versus 1.0%
± 0.2%/pt-y for an SJ prosthesis (P = .2). 
Ten-year freedom from endocarditis was not signifi-
cantly different between patients with a CE prosthesis
and patients with an SJ prosthesis (96% ± 1% vs 97%
± 1%; P = .5; Fig 3). By Cox model analysis, the only
variable predictive of late endocarditis was preopera-
tive endocarditis (b = 2.3 ± .5; c 2 = 20.5; P = .0001),
and age did not significantly affect late endocarditis.
The linearized rates of endocarditis were 0.4% ±
0.1%/pt-y for patients with a CE prosthesis and 0.4% ±
0.1%/pt-y for patients with an SJ prosthesis (P = .9).
Ten-year freedom from aortic valve reoperation was
significantly better for patients with an SJ prosthesis
(98% ± 1% vs 83% ± 3%; P = .02). By Cox model
analysis, the only independent variables predictive of
aortic valve reoperation were CE valve make (b = –1.0
± .4; c 2 = 6.6; P = .01) and younger patient age (b =
–.044 ± .009; c 2 = 25.2; P = .0001). For patients over
65 years old, valve make did not affect aortic valve
reoperation (P = .4, Fig 4). For patients aged 65 years
and younger, freedom from reoperation was signifi-
cantly better for an SJ versus a CE prosthesis (P = .02;
Fig 4). After reoperation, the 30-day mortality rate was
4 of 63 (6%) for all patients and 1 of 9 (11%) in all
patients with coronary bypass grafting with the original
aortic valve operation.
Survival free from valve-related morbidity. After
an examination of all 841 study patients, there was no
significant difference in survival free from valve-relat-
ed morbidity (defined earlier) between patients receiv-
ing a CE versus an SJ prostheses (43% ± 3% vs 41% ±
5%; P = .8; Fig 5). By Cox model analysis, indepen-
dent multivariable factors predicting worse survival
free from valve-related morbidity were ejection frac-
tion less than 40% (c 2 = 11.9; P = .0005), renal disease
(c 2 = 10.1; P = .002), diabetes (c 2 = 8.2; P = .004), and
coronary artery disease (c 2 = 6.5; P = .01). For the
entire pool of 841 patients, make of valve (CE vs SJ)
and year of operation were not significant predictors of
survival free from valve-related morbidity.
Because age was a determinant of both survival and
reoperation, survival free from valve-related morbidity
was examined as a function of patient age. At 10 years
after operation, survival free from valve-related mor-
bidity was better with CE valves in patients over 65
years old and was better with SJ valves in patients
under 65 years old (Fig 1).
For patients not surviving 10 years, CE bioprostheses
would be preferable because of the absence of antico-
agulant-related hemorrhage and because of the rarity of
reoperation within 10 years in these patients. Several
groups of patients with a life expectancy less than 10
years (thus favoring bioprostheses) included patients
over 65 years old, patients with lung disease who are
under age 60 years, and patients at any age with renal
disease, ejection fraction less than 40%, or coronary
Fig 5. Survival free from valve-related morbidity after aortic
valve replacement with the CE or SJ prostheses.




Ten-year reoperation on 
survival (%) CE aortic valve (%)
Renal disease, any age 27 ± 8 100 ± 0
Lung disease (patient older than 30 ± 6 96 ± 2
60 y)
Ejection fraction < 40%, any age 35 ± 6 95 ± 2
Coronary artery disease, any age 35 ± 5 98 ± 0.8
Age > 65 y 41 ± 4 98 ± 0.7
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disease. Even in patients under 55 years old, the pres-
ence of coronary disease produced a 10-year survival of
35% ± 13% for patients with a CE prosthesis and
patients with an SJ prosthesis combined. For patients in
any of these groups who received a CE bioprosthesis,
the actual 10-year freedom from aortic valve reopera-
tion15 was at least 95% (Table IV).
Discussion
Only a few large studies have compared outcomes
between biologic and mechanical valve replacement;
the results of the most recent studies are summarized in
Table V. The current study confirmed a greater inci-
dence of hemorrhage with mechanical versus biologic
valves.8-11,18 The hemorrhage rate with mechanical
prostheses in this study (1.2% ± 0.3%/pt-y) was some-
what less than the 2%/pt-y reported in most series.8-11,18
This difference may result from the low-risk population
(first-time isolated aortic valve replacement) and the
recent time frame in this study where anticoagulation
was maintained at lower levels than in earlier years.
The thromboembolic rate of this study is comparable
with other reports for both biologic and mechanical
prostheses.8-11,18 This study confirms the higher inci-
dence of aortic valve reoperation in patients receiving a
bioprosthesis and in younger patients.19
This retrospective analysis of 841 patients differs
from previous studies in several respects. No recent
study compared the modern CE and SJ prostheses,20,21
and the current study is the third largest study compar-
ing biologic and mechanical aortic valves to date.13,21
In the two larger series, both biologic and mechanical
patient groups included several makes of prostheses,
which may differ in durability, flow characteristics, or
thrombogenicity.13.21 Only the Cleveland Clinic study
with multiple valve makes used multivariable analysis
to examine the effects of comorbidity on survival after
biologic versus mechanical aortic valve replacement.
The Cleveland Clinic study confirmed that age and
mechanical prostheses impaired event-free survival,
but only in patients over age 60 years or not receiving
anticoagulation over age 40 years.21
The current study is the first to provide numeric data
supporting guidelines to select biologic versus mechan-
ical devices based on patient comorbidity other than
age (Table IV). The current study provides data that
support a specific age (65 years) over which survival
free from valve-related events is better with biologic
valves,22,23 although outcome tended to be better with
mechanical valves in younger patients (Table IV; Fig
1). Previous studies not examining comorbidities other
than coronary disease have placed the cutoff for bio-
logic versus mechanical prostheses at 65 to 70
years.22,23 Patient selection bias (eg, patients with bio-
logic valves having significantly less coronary disease)
may explain why the Cleveland Clinic study showed
better event-free survival with bioprostheses in patients
over age 40 years.21
The significantly higher incidence of early perivalvu-
lar leak rate in the SJ group has not been previously
reported. Explanations for this finding may include dif-
ferences in sewing ring width and shape between SJ
and CE prostheses, along with the tendency to use SJ
prostheses in smaller aortic roots where valve seating
may be more difficult (Table I). SJ and other valve
makes are now available with large sewing rings that
were not used in this study.
The nonrandomized, retrospective nature of this
study limits the findings. The major bias between the
CE and SJ groups was the earlier year of operation and
the resultant higher 30-day mortality in patients with a
CE prosthesis. One possible effect of overestimating
early deaths after CE aortic valve replacement may be
to underestimate 10-year survival free from valve-relat-
ed morbidity in patients with a CE prosthesis. In turn,
this bias may mean that the CE and SJ curves in Fig 1
actually should cross at age 65 years instead of age 70
years. These data therefore suggest that the age at
Table V. Linearized rates of complications
Peterseim, Holper et al,9 Myken et al,11 Hammermeister et al,8 Bloomfield et al,18 
1999 1995 1995 1993 1991 
(nonrandomized) (nonrandomized) (nonrandomized) (randomized) (randomized)
Bio Mech Bio Mech Bio Mech Bio Mech Bio Mech 
Complication (n = 429) (n = 412) (n = 326) (n = 250) (n = 100) (n = 100) (n = 196) (n = 198) (n = 102) (n = 109)
Hemorrhage (%/pt-y) 0.3 1.2 0.94 3.0 0.1 2.3 2.2 3.9 0.81 2.7
Thromboembolism 0.7 1.0 1.29 1.32 0.6 1.2 1.4 1.5 1.9 0.96
Leak (%/pt-y) 0.7 1.0 0.14 0.24 0.18 0.36
Endocarditis (%/pt-y) 0.4 0.4 0.14 0.36 0.6 0.5 0.73 0.64 0.18 0.4
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which CE valves become advantageous is 65 years in
this patient population. 
An additional shortcoming of this study is the limit-
ed follow-up in the SJ group after 10 years, at which
time differences between biologic and mechanical
valves may be magnified by increased reoperation for
structural deterioration of the bioprostheses. Fifteen-
year data await further study; however, the conclusions
of this study are based on 10-year results and are
unlikely to be changed by data from the small number
of patients surviving 15 years or more. Although the
current study was limited to first-time isolated aortic
valve procedures (with or without coronary bypass
grafting), the results could well be different in patients
with a previous cardiac operation or multiple valve
operations.10 Although this study is among the largest
studies to date, the small patient numbers in some sub-
groups may have limited the ability to define ages
where life expectancy could exceed 10 years and where
results might therefore favor mechanical prostheses
(eg, young patients with coronary disease; Table IV). In
addition, the presence of previous coronary grafts in a
young patient undergoing reoperation for a failed bio-
prosthesis could increase late mortality rates, although
the reoperative mortality was a modest 11% for
patients of all ages with previous coronary bypass
grafts in the current study. The reported mortality rate
for aortic valve operation has been 14% after previous
coronary bypass24 and as low as 8% after previous aor-
tic valve replacement.25
The current study evaluated a second generation
porcine bioprosthesis that has been partly displaced by
pericardial bioprostheses (models 2700 and 2800;
Baxter Healthcare Corp). Yet, the study is still relevant
because pericardial and porcine aortic prostheses have
similar durability and performance characteristics.26-29
The SJ valve (model A102) used in this study continues
to be widely used.30,31
Choice of an aortic bioprosthesis versus mechanical
prosthesis should be individualized on the basis of the
patient’s ability to take warfarin and the patient’s age
and life expectancy. This choice primarily is one of
increased likelihood of reoperation with bioprostheses
versus increased likelihood of hemorrhage with
mechanical prostheses. The relatively low 10-year sur-
vival of 50% to 54% and the high frequency of cardiac
deaths (Table III) suggest that other factors, such as
optimal timing of operation, may be more important to
survival than prosthesis selection. The results of this
study support the general philosophy that older, sicker
patients tend to benefit more from bioprostheses and
that younger, healthier patients should receive
mechanical prostheses. Otherwise, patients who are
unable to reliably take warfarin or who have medical
illnesses precluding anticoagulation should receive a
bioprosthesis.
The current study provides data that suggest age cut-
off points for selecting biologic versus mechanical
valves in different patient subgroups (Table IV; Fig 1).
Patients with an expected survival of less than 10 years
(more than 65 years old, renal disease, lung disease,
patients who are more than 60 years old), ejection frac-
tion of less than 40%, or coronary disease (Table IV;
Fig 1) would be reasonable candidates for aortic bio-
prostheses to avoid anticoagulation with an extremely
low likelihood of aortic valve reoperation (Table IV).
Results tend to favor mechanical aortic valves in
patients under age 65 years with a life expectancy of at
least 10 years (Fig 1). Specific subsets of patients
undergoing multiple valve operation or repeat cardiac
operation merit further investigation.10
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Appendix
Preoperative variables included in Cox proportional
hazards models:
Valve type
Age older than 65 years
Sex
Ejection fraction less than 40%
Operation year







Number of diseased coronary vessels
Peptic ulcer disease
Previous gastrointestinal hemorrhage
Endocarditis within 6 months
